Irritable Bowel Syndrome 
The MD Magazine Irritable Bowel Syndrome condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.


Synergy Pharmaceuticals Submits NDA for IBS-C Drug Plecanatide
Pharma submits sNDA for IBS-C drug plecanatide.
IBS-D treatment eluxadoline is a risk for patients who do not have gallbladders.
New trial tests efficacy of CanChew Plus cannabidiol gum to treat IBS.
HOST-G904 showed positive results for treating severe bowel conditions.
Patients suffering from irritable bowel syndrome with constipation (IBS-C) may benefit from a new drug, plecanatide, making its way through the approval pipeline.
Alternative therapies such as probiotics and synbiotics may be viable options for patients with irritable bowel disorders, according to findings published in the British Journal of Pharmacology.
Patients experiencing pain from irritable bowel syndrome (IBS) might find relief from an unlikely source.
Arachnophobes suffering from irritable bowel syndrome (IBS) may have to put their fear on hold to welcome pain relief from their gastrointestinal condition.
The development of new medications for any condition requires attention to detail in a number of areas, especially safety and efficacy. A recent drug developed for irritable bowel syndrome (IBS) looked to be effective in both areas prior to its approval.

Most Popular


$vacMongoViewPlus$ $vAR$